Last reviewed · How we verify

NCT05196698: HIFAE

Home High Flow Oxygen to Reduce Acute Exacerbation of COPD

Recruiting now NA Last updated 6 February 2026
What this trial tests

NA trial testing High Flow Oxygen Therapy in Chronic Obstructive Pulmonary Disease in 406 participants. Currently enrolling.

Timeline
26 August 2022
Primary endpoint
26 August 2026
26 August 2026

Quick facts

Lead sponsorUniversity Hospital, Rouen
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment406
Start date26 August 2022
Primary completion26 August 2026
Estimated completion26 August 2026
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Rouen

Who can join

Adults 18 to 85, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to evaluate the efficacy of home High Flow Oxygen for the reduction of severe exacerbation following admission for a severe exacerbation of COPD or death against standard oxygen therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Highlights from the Respiratory Failure and Mechanical Ventilation Conference 2024.
    Bianquis C, De Leo G, Morana G, Duarte-Silva M, et al · · 2024 · PMID 39534488 · DOI 10.1183/20734735.0105-2024

Verify or expand the search:

Other trials of High Flow Oxygen Therapy

Trials testing the same drug.

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other University Hospital, Rouen trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05196698.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing